Literature DB >> 12605580

5-Hydroxytryptamine 5-HT2A receptor and 5-hydroxytryptamine transporter polymorphisms in acute myocardial infarction.

Eliecer Coto1, Julián R Reguero, Victoria Alvarez, Blanca Morales, Alberto Batalla, Pelayo González, María Martín, Mónica García-Castro, Gustavo Iglesias-Cubero, Arturo Cortina.   

Abstract

This study was designed to analyse possible associations between DNA polymorphisms in the 5-hydroxytryptamine (5-HT; serotonin) 5-HT(2A) receptor and the 5-HT transporter (5-HTT) genes, and myocardial infarction (MI). 5-HT has been shown to be involved in cardiovascular pathophysiology. In addition to platelet aggregation and vascular contraction, 5-HT induces hyperplasia of artery smooth muscle cells. Recently, a 5-HT transporter gene polymorphism has been associated with MI. To determine the influence of genetic variation at the 5-HT(2A) receptor (T102C polymorphism) and the 5-HTT (insertion/deletion polymorphism) on the risk of developing early MI, we genotyped 210 MI patients of < 55 years old and 238 healthy control subjects for DNA polymorphisms in these genes. In addition, we genotyped 95 patients with late-onset MI (> 60 years old) to analyse the effects of these polymorphisms on the age at which the first MI episode occurred. The 5-HT(2A) receptor polymorphism was not associated with MI in our population. In addition, since the 5-HT(2A) receptor gene and genotype frequencies did not differ between patients with early and late onset of MI, this polymorphism does not appear to have an effect on age at the first MI episode. Gene and genotype frequencies for the 5-HTT promoter did not differ between patients < 55 years old and healthy controls (independent of smoking status). However, homozygotes for the deletion (the ss genotype, where s denotes the short allele) were present at a significantly higher frequency in patients >60 years old compared with patients < 55 years old (P = 0.009; P = 0.004 when only smokers were compared). According to our data, the ss genotype would seem to have a protective role against MI, delaying the age of onset of the first episode, especially among smokers. This could be a consequence of the lower 5-HTT levels linked to the s allele, so that individuals homozygous for the ss genotype may have lower 5-HT re-uptake by platelets.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12605580     DOI: 10.1042/CS20020246

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  12 in total

Review 1.  Executive (dys)function after stroke: special considerations for behavioral pharmacology.

Authors:  Jessica M Povroznik; Jenny E Ozga; Cole Vonder Haar; Elizabeth B Engler-Chiurazzi
Journal:  Behav Pharmacol       Date:  2018-10       Impact factor: 2.293

2.  Effects of 5HTTLPR on cardiovascular response to an emotional stressor.

Authors:  Beverly H Brummett; Ilene C Siegler; Allison Ashley-Koch; Redford B Williams
Journal:  Psychosom Med       Date:  2011-03-01       Impact factor: 4.312

3.  Population differences in associations of serotonin transporter promoter polymorphism (5HTTLPR) di- and triallelic genotypes with blood pressure and hypertension prevalence.

Authors:  Redford B Williams; George D Bishop; Brett C Haberstick; Andrew Smolen; Beverly H Brummett; Ilene C Siegler; Michael A Babyak; Xiaodong Zhang; E Shyong Tai; Jeannette Jen-Mai Lee; Maudrene Tan; Yik Ying Teo; Shiwei Cai; Edmund Chan; Carolyn Tucker Halpern; Eric A Whitsel; Shawn Bauldry; Kathleen Mullan Harris
Journal:  Am Heart J       Date:  2016-12-29       Impact factor: 4.749

Review 4.  Lower urinary tract symptoms, benign prostatic hyperplasia and metabolic syndrome.

Authors:  Linda Vignozzi; Mauro Gacci; Mario Maggi
Journal:  Nat Rev Urol       Date:  2016-01-12       Impact factor: 14.432

5.  Interaction of serotonin transporter gene-linked polymorphic region and stressful life events predicts cortisol stress response.

Authors:  Anett Mueller; Diana Armbruster; Dirk A Moser; Turhan Canli; Klaus-Peter Lesch; Burkhard Brocke; Clemens Kirschbaum
Journal:  Neuropsychopharmacology       Date:  2011-03-02       Impact factor: 7.853

6.  Hyperreactive platelet phenotypes: relationship to altered serotonin transporter number, transport kinetics and intrinsic response to adrenergic co-stimulation.

Authors:  Jeffrey S Berger; Richard C Becker; Cynthia Kuhn; Michael J Helms; Thomas L Ortel; Redford Williams
Journal:  Thromb Haemost       Date:  2012-12-06       Impact factor: 5.249

Review 7.  How the serotonin story is being rewritten by new gene-based discoveries principally related to SLC6A4, the serotonin transporter gene, which functions to influence all cellular serotonin systems.

Authors:  Dennis L Murphy; Meredith A Fox; Kiara R Timpano; Pablo R Moya; Renee Ren-Patterson; Anne M Andrews; Andrew Holmes; Klaus-Peter Lesch; Jens R Wendland
Journal:  Neuropharmacology       Date:  2008-09-11       Impact factor: 5.250

8.  Functional polymorphisms in genes of the Angiotensin and Serotonin systems and risk of hypertrophic cardiomyopathy: AT1R as a potential modifier.

Authors:  Eliecer Coto; María Palacín; María Martín; Mónica G Castro; Julián R Reguero; Cristina García; José R Berrazueta; César Morís; Blanca Morales; Francisco Ortega; Ana I Corao; Marta Díaz; Beatriz Tavira; Victoria Alvarez
Journal:  J Transl Med       Date:  2010-07-01       Impact factor: 5.531

9.  Disturbance of serotonergic neurotransmission in patients with postmyocardial infarction and depression.

Authors:  Gabriel Manjarrez-Gutiérrez; Rodolfo Ramírez-Campillo; Gabriela Borrayo-Sánchez; Jorge Hernández-Rodríguez
Journal:  Metab Brain Dis       Date:  2012-11-06       Impact factor: 3.584

Review 10.  The role of prolactin in andrology: what is new?

Authors:  Giulia Rastrelli; Giovanni Corona; Mario Maggi
Journal:  Rev Endocr Metab Disord       Date:  2015-09       Impact factor: 6.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.